Schering-Plough Corp., the drugmaker acquired by Merck & Co., won a U.S. judge’s approval of a $165 million settlement to resolve lawsuits over alleged fraudulent statements to investors about the Clarinex allergy medicine.
Continue reading here:
Schering-Plough enters $165M Clarinex accord